BackU-Neuron Biomedical Overview

U-Neuron Biomedical Profit Margin

U-Neuron Biomedical (6973.TWO) has a profit margin of -68.01%, below the Healthcare sector average of 10.58%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-51.20%
↑ 12.58% YoY

As of Jun 2026

Annual Profit Margin (TTM)

-68.01%

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

U-Neuron Biomedical (6973.TWO) FAQ

U-Neuron Biomedical's profit margin stands at -68.01% as of June 2026. That is below the Healthcare sector average of 10.58%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

U-Neuron Biomedical sits lower the Healthcare benchmark (10.58%) with a profit margin of -68.01%. That is roughly 742.8% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -68.01% for U-Neuron Biomedical means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how U-Neuron Biomedical's profit margin evolved across reporting periods, while the comparison chart places 6973.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, profit margin is commonly used to spot outliers. U-Neuron Biomedical's reading of -68.01% (sector avg 10.58%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.